The impact of low-grade toxicity in older people with cancer undergoing chemotherapy

British Journal of Cancer

Volumn 111, Issue 12, 2014, Pages 2224-2228

  Kalsi, T ^a   Babic Illman, G ^b   Fields, P ^a   Hughes, S ^a   Maisey, N ^a   Ross, P ^a   Wang, Y ^a   Harari, D ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

chemotherapy; elderly; geriatric oncology; low grade toxicity

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADVERSE DRUG REACTION; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL PRACTICE; COHORT ANALYSIS; COMORBIDITY; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM CANCER; FATIGUE; FEMALE; GYNECOLOGIC CANCER; HUMAN; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; NAUSEA; OBSERVATIONAL STUDY; PERIPHERAL NEUROPATHY; PHYSICIAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT PLANNING; TREATMENT WITHDRAWAL; UNITED KINGDOM; VERY ELDERLY; AGE; NEOPLASMS;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MALE; NEOPLASMS;

EID: 84927579193     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.496     Document Type: Article

References (37)

1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JCJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5): 365-376.
2. Balducci L (2003) New paradigms for treating elderly patients with cancer: the comprehensive geriatric assessment and guidelines for supportive care. J Support Oncol 1(4 Suppl 2): 30-37.
3. Benson AB, Pregler JP, Bean JA, Rademaker AW, Eshler B, Anderson K (1991) Oncologists' reluctance to accrue patients onto clinical trials: an Illinois Cancer Center study. J Clin Oncol 9(11): 2067-2075.
4. Chen H, Cantor A, Meyer J, Corcoran MB, Grendys E, Cavanaugh D, Antonek S, Camarata A, Haley W, Balducci L, Extermann M (2003) Can older cancer patients tolerate chemotherapy? A prospective pilot study. Cancer 97(4): 1107-1114.
5. Department of Health (2012). https://www.gov.uk/government/publications/improving-older-peoples-access-to-cancer-treatment-services.
6. Droz JP, Aapro M, Balducci L (2008) Overcoming challenges associated with chemotherapy treatment in the senior adult population. Crit Rev Oncol Hematol 68(1): 26.
7. Extermann M, Aapro M, Bernabei R, Cohen HJ, Droz JP, Lichtman S, Mor V, Monfardini S, Repetto L, Sorbye L, Topinkova E (2005) Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55(3): 241-252.
8. Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, DeFelice J, Levine RM, Lubiner ET, Reyes P, Schreiber FJ, Balducci L (2011) Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 118(13): 3377-3386.
9. Fisher S, Al-Fayea TM, Winget M, Gao H, Butts C (2012) Uptake and tolerance of chemotherapy in elderly patients with small cell lung cancer and impact on survival. J Cancer Epidemiol 2012(708936): 29.
10. Garcia-Suarez J, Krsnik I, Reyes E, De Miguel D, Hernanz N, Barr-Ali M, Burgaleta C (2003) Elderly haematological patients with chemotherapyinduced febrile neutropenia have similar rates of infection and outcome to younger adults: a prospective study of risk-adapted therapy. Br J Haematol 120(2): 209-216.
11. Giovanazzi-Bannon S, Rademaker A, Lai G, Benson AB (1994) Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: an Illinois Cancer Center study. J Clin Oncol 12(11): 2447-2452.
12. Girre V, Falcou MC, Gisslebrecht M, Gridel G, Mosseri V, Bouleuc C, Poinsot R, Vedrine L, Ollivier L, Garabige V, Piera JY, Dieras V, Mignot L (2008) Does a geriatric oncology consultation modify the cancer treatment plan for elderly patients? J Gerontol A Biol Sci Med Sci 63(7): 724-730.
13. Goldberg RM, Tabah-Fisch I, Bleiberg H, De Gramont A, Tournigand C, Andre T, Rothenberg ML, Green E, Sargent DJ (2006) Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24(25): 4085-4091.
14. Gosney M.A (2005) Clinical assessment of elderly people with cancer. Lancet Oncol 6(10): 790-797.
15. Hurria A, Gupta S, Zauderer M, Zuckerman EL, Cohen HJ, Muss H, Rodin M, Panageas KS, Holland JC, Saltz L, Kris MG, Noy A, Gomez J, Jakubwski A, Hudis C, Kornblith AB (2005) Developing a cancer-specific geriatric assessment: a feasibility study. Cancer 104(9): 1998-2005.
16. Hurria A, Lichtman SM, Gardes J, Li D, Limaye S, Patil S, Zuckerman E, Tew W, Hamlin P, Abou-Alfa K, Lachs M, Kelly E (2007) Identifying vulnerable older adults with cancer: integrating geriatric assessment into oncology practice. J Am Geriatr Soc 55(10): 1604-1608.
17. Ingram SS, Seo PH, Martell RE, Clipp EC, Doyle ME, Montana GS, Cohen HJ (2002) Comprehensive assessment of the elderly cancer patient: the feasibility of self-report methodology. J Clin Oncol 20(3): 770-775.
18. Jantunen E, Kuittinen T, Penttila K, Lehtonen P, Mahlamaki E, Nousiainen T (2006) High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (65 years) myeloma patients: comparison with younger patients treated on the same protocol. Bone Marrow Transplant 37(10): 917-922.
19. Kalsi T, Babic-Illman G, Duraisingham SL, Ross P, Maisey N, Hughes S, Fields P, Brodie H, Wang Y, Harari D (2013) Feasibility and utility of comprehensive geriatric assessment screening via postal questionnaire (CGA-GOLD) in older people with cancer. European Geriatric Medicine 4(Suppl 1): 96.
20. Kalsi T, Babic-Illman G, Hughes S, Ross P, Fields P, Maisey N, Brodie H, Wang Y, Harari D (2014) Validity & reliability of a comprehensive geriatric assessment screening questionnaire (CGA-GOLD) in older people with cancer. Age Ageing 43(Suppl 1): i30.
21. Kalsi T, Payne S, Brodie H, Mansi J, Wang Y, Harari D. (2013) Are the UK oncology trainees adequately informed about the needs of older people with cancer. Br J Cancer 108(10): 1936-1941.
22. Lichtman SM, Wildiers H, Chatelut E, Steer C, Budman D, Morrison VA, Tranchand B, Shapira I, Aapro M (2007) International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients-an analysis of the medical literature. J Clin Oncol 25(14): 1832-1843.
23. Llopis-Salvia P, Sarrio-Montes G, Garcia-Llopis P, Bargues-Ruiz A (2010) Chemotherapy dose intensity reductions due to adverse drug reactions in an oncology outpatient setting. J Oncol Pharm Pract 16(4): 256-261.
24. Luciani A, Marussi D, Ascione G, Caldiera S, Ferrari D, Oldani S, Uziel L, Zonato S, Foa P (2006) Do elderly cancer patients achieve an adequate dose intensity in common clinical practice? Oncology 71(5-6): 382-387.
25. Marenco D, Marinello R, Berruti A, Gaspari F, Stasi MF, Rosato R, Bertetto O, Molaschi M, Ciccone G (2008) Multidimensional geriatric assessment in treatment decision in elderly cancer patients: 6-year experience in an outpatient geriatric oncology service. Crit Rev Oncol Hematol 68(2): 157-164.
26. Minisini A, Atalay G, Bottomley A, Puglisi F, Piccart M, Biganzoli L (2004) What is the effect of systemic anticancer treatment on cognitive function? Lancet Oncol 5(5): 273-282.
27. Mitry E, Rougier P (2009) Review article: benefits and risks of chemotherapy in elderly patients with metastatic colorectal cancer. Aliment Pharmacol Ther 29(2): 161-171.
28. Mohile SG, Bylow K, Dale W, Dignam J, Martin K, Petrylak DP, Sadler WM, Rodin M (2007) A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. Cancer 109(4): 802-810.
29. Park SC, Whan LJ, Sik RJ (2012) Docetaxel-based systemic chemotherapy in elderly Korean men with castration-resistant prostate cancer. Actas Urol Esp 36(7): 425-430.
30. Rodin MB, Mohile SG (2007) A practical approach to geriatric assessment in oncology. J Clin Oncol 25(14): 1936-1944.
31. Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, Shepherd LE, Seitz JF, Francini G (2001) A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345(15): 1091-1097.
32. Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ (1995) Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 75(1): 11-17.
33. Terret C, Albrand G, Droz JP (2004) Geriatric assessment in elderly patients with prostate cancer. Clin Prostate Cancer 2(4): 236-240.
34. Tsalic M, Bar-Sela G, Beny A, Visel B, Haim N (2003) Severe toxicity related to the 5-fluorouracil/leucovorin combination (the Mayo Clinic regimen): a prospective study in colorectal cancer patients. Am J Clin Oncol 26(1): 103-106.
35. Wedding U, Honecker F, Bokemeyer C, Pientka L, Hoffken K (2007) Tolerance to chemotherapy in elderly patients with cancer. Cancer Control 14(1): 44-56.
36. Wu C, Goldberg RM (2013) Managing choices for older patients with colon cancer. Am Soc Clin Oncol Educ Book 2013: 190-193.
37. Yee KW, Pater JL, Pho L, Zee B, Siu LL (2003) Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? J Clin Oncol 21(8): 1618-1623.